Global Amyotrophic Lateral Sclerosis Treatment Market Growth (Status and Outlook) 2023-2029

Global Amyotrophic Lateral Sclerosis Treatment Market Growth (Status and Outlook) 2023-2029

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

LPI (LP Information)' newest research report, the “Amyotrophic Lateral Sclerosis Treatment Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis Treatment sales for 2023 through 2029. With Amyotrophic Lateral Sclerosis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis Treatment industry.

This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis Treatment.

The global Amyotrophic Lateral Sclerosis Treatment market size is projected to grow from US$ 293.5 million in 2022 to US$ 373.6 million in 2029; it is expected to grow at a CAGR of 3.5% from 2023 to 2029.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Medication
Physical Therapy
Speech Therapy
Others

Segmentation by application
Hospitals
Specialty Centers
Research Centers
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Roche
Biogen
Mitsubishi Tanabe Pharma
GNT Pharma
Synthetic Biologics
Amkor Pharma
ViroMed
Brainstorm Therapeutics
Bausch Health

Please note: The report will take approximately 2 business days to prepare and deliver.